Elevance Health has entered a national agreement with CNSide Diagnostics to offer a cerebrospinal fluid tumor cell assay to about 45.4 million covered lives starting May 1, 2026, while simultaneously rolling out its Health OS data platform and digital programs aimed at streamlining clinical decisions and reducing prior authorization friction. Early results from Health OS show fewer prior authorization denials and faster clinical reviews, which could support Elevance's cost management efforts, though bears remain concerned that persistent high medical costs in ACA and Medicaid plans may offset any efficiency gains. The company's long-term narrative projects $230.4 billion in revenue and $7.4 billion in earnings by 2028, requiring 6.8% annual revenue growth and a $2.0 billion earnings increase from the current $5.4 billion. Some analysts are more cautious, estimating revenue around $204.8 billion and earnings near $6.5 billion by 2029, citing elevated government plan costs and regulatory uncertainty as potential headwinds.
Elevance Health IncElevance Health enters national agreement for CNSide assay and rolls out Health OS platform, which streamlines clinical decisions and reduces prior authorization friction.
CNSide Diagnostics secures national agreement with Elevance Health, covering 45.4 million lives starting May 2026.